CFN Media CEO Interview: InMed Pharmaceuticals’ Biosynthesis Platform Results in an Industry First

Read our Medical Marijuana Compound Report for Free Today!

The next big innovation is unfolding now and it’s already creating a wave of multi-millionaire investors in the process

Read the Investors Guide To Newly Emerging Marijuana Markets

Dear Seed Investor,

CFN Media today released an exclusive interview with Eric Adams, CEO of InMed Pharmaceuticals.

It is a very interesting discussion about the companies recent research, and the implications that it could have on the cannabis biosynthesis industry as a whole.

As you know, we've been championing InMed as a potential big winner in the cannabis biosynthesis space, due to their proprietary biosynthesis process, the results they've already been announcing, and the strong management and advisory team they have put in place.

If you are interested in InMed, we recommend viewing this interview.

CLICK TO WATCH INTERVIEW

High Profits,

The Seed Investor

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed investment advisor.

TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260

info@theseedinvestor.com

To keep receiving emails from us, please add us to your address book.